List view / Grid view
Eurofins CDMO provides full range of drug development and manufacturing services from formulation screening and development, analytical development, stability studies and pre-clinical safety assessment studies to sterile and non-sterile manufacturing, IND/ IMPD and NDA/ CTD services, as well as clinical trial material including packaging and logistics.
As maintaining the health of the chemist is of top priority, one should recognise potential dangers that can jeopardise the safety of laboratory staff and install measures to sufficiently protect the scientists.
A project backed by major pharma will advance the Lab of the Future with proof of concept software to digitise experiment methods…
Oxford Genetics has won six new licensing deals for its scalable drug and gene therapy manufacturing in the synthetic biology sector...
High-throughput mass spectrometry (MS)-based proteomics approaches have developed enormously in recent years and are continuing to do so. The current trend sees proteomics being used by academia and industry to tackle intricate biological questions, often in conjunction with other high-throughput “omics” disciplines such as genomics, transcriptomics and metabolomics. Within the…
Researchers have developed a microscope that may provide insight into how safely and effectively a drug will perform in the body...
A New Drug Application has been made to the US Food and Drug Administration for the drug darolutamide to treat non-metastatic prostate cancer...
For decades, near-infrared (NIR) spectroscopy has been an invaluable tool within the laboratory and, interestingly, despite all the excellent instrumentation and technologies introduced for process control, NIR is still the most popular and mature technique available. This article will discuss the impact of NIR in pharmaceuticals from the perspective of…
Strong regimentation and economic interests demand the development and implementation of new techniques for process control and analysis in the pharmaceutical industry. The extensive analysis of all deployed materials, intermediates and products leads to a higher degree of process stability and can contribute to a faster compensation for deviations, especially…
The global antibiotics market is set to increase at a CAGR of 4 percent to $62.06 billion, due to the rising prevalence of infectious diseases...
In this issue: identification of peptides and proteins in suspected illegal medicinal products using MALDI-TOF-MS, and open data policies in proteomics.
Matrix-assisted laser desorption/ionisation (MALDI) time-of-flight (TOF) mass spectrometry (MS) has proven to be an excellent technique for identification of illegally distributed peptides and proteins for human use. The identification of proteins is mainly based on peptide mass fingerprinting (PMF) – ie, the bottom-up approach – while the small proteins and…
This near-infrared spectroscopy In-Depth Focus looks at online drying process control of pharmaceutical intermediates and how NIR has moved on from the lab.
General Electric is selling its biopharma business for $21.4 billion, with shares in the company jumping 16 percent upon the news...
In this edition of our 'Guide to' series we look at analytical testing instruments from SUEZ.
